191 related articles for article (PubMed ID: 1379060)
21. Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).
Rapoport B; Chua D; Poma A; Arora S; Wang Y; Fein LE
Support Care Cancer; 2015 Nov; 23(11):3281-8. PubMed ID: 25940030
[TBL] [Abstract][Full Text] [Related]
22. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
23. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.
Gralla RJ; de Wit R; Herrstedt J; Carides AD; Ianus J; Guoguang-Ma J; Evans JK; Horgan KJ
Cancer; 2005 Aug; 104(4):864-8. PubMed ID: 15973669
[TBL] [Abstract][Full Text] [Related]
24. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
Massidda B; Ionta MT
J Chemother; 1996 Jun; 8(3):237-42. PubMed ID: 8808724
[TBL] [Abstract][Full Text] [Related]
25. Acute and delayed nausea and emesis control in pediatric oncology patients.
Holdsworth MT; Raisch DW; Frost J
Cancer; 2006 Feb; 106(4):931-40. PubMed ID: 16404740
[TBL] [Abstract][Full Text] [Related]
26. Serotonin metabolism following platinum-based chemotherapy combined with the serotonin type-3 antagonist tropisetron.
Schröder CP; van der Graaf WT; Kema IP; Groenewegen A; Sleijfer DT; de Vries EG
Cancer Chemother Pharmacol; 1995; 36(6):477-82. PubMed ID: 7554039
[TBL] [Abstract][Full Text] [Related]
27. [Mechanisms of cytotoxic drug-induced emesis and its prevention].
Matsuki N
Yakugaku Zasshi; 1996 Sep; 116(9):710-8. PubMed ID: 8855716
[TBL] [Abstract][Full Text] [Related]
28. Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II study.
Mandalà M; Cremonesi M; Rocca A; Cazzaniga M; Ferretti G; Di Cosimo S; Ghilardi M; Cabiddu M; Barni S
Support Care Cancer; 2005 Jun; 13(6):375-80. PubMed ID: 15668754
[TBL] [Abstract][Full Text] [Related]
29. Management of other non-cisplatin-induced emesis.
Schmoll HJ; Casper J
Oncology; 1996 Jun; 53 Suppl 1():51-5. PubMed ID: 8692552
[TBL] [Abstract][Full Text] [Related]
30. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting].
Depierre A
Bull Cancer; 1996 Feb; 83(2):147-53. PubMed ID: 8652909
[TBL] [Abstract][Full Text] [Related]
32. Serotonin and emesis--from animals to humans: a discussion of Professor Naylor's paper.
Cubeddu L; Hoffmann I; Fuenmayor N
Br J Cancer Suppl; 1992 Dec; 19():S9-11. PubMed ID: 1281668
[No Abstract] [Full Text] [Related]
33. A randomized trial of two doses of granisetron in the treatment of chemotherapy-induced emesis. Dutch results within a multinational study.
Bots MW; Dijkstra HJ; Blijham GH; van der Wall E; Fehmers MC; Keizer HJ; Nortier JW; Siegenbeek van Heukelom L; Slee PH; Veenhof CH
Neth J Med; 1992 Jun; 40(5-6):221-6. PubMed ID: 1331830
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials.
Beck TM
Semin Oncol; 1992 Dec; 19(6 Suppl 15):20-5. PubMed ID: 1485178
[TBL] [Abstract][Full Text] [Related]
35. Reducing chemotherapy-induced nausea and vomiting. Current perspectives and future possibilities.
Del Favero A; Roila F; Tonato M
Drug Saf; 1993 Dec; 9(6):410-28. PubMed ID: 7510495
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy.
Burris H; Hesketh P; Cohn J; Moriconi W; Ryan T; Friedman C; Fitts D
Cancer J Sci Am; 1996; 2(2):85-90. PubMed ID: 9166505
[TBL] [Abstract][Full Text] [Related]
37. [Recent improvements in antiemetic therapy].
Roila F; Palladino MA; Ciccarese G; Basurto C
Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
[TBL] [Abstract][Full Text] [Related]
39. Antiemetic therapy for non-anthracycline and cyclophosphamide moderately emetogenic chemotherapy.
Inui N
Med Oncol; 2017 May; 34(5):77. PubMed ID: 28365889
[TBL] [Abstract][Full Text] [Related]
40. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.
Cubeddu LX; Hoffman IS; Fuenmayor NT; Finn AL
J Clin Oncol; 1990 Oct; 8(10):1721-7. PubMed ID: 2145400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
